

02 SEPTEMBER 2004 02.09.04

PA 1192151

THE UNITED STATES OF AMERICA**TO ALL TO WHOM THESE PRESENTS SHALL COME:****UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

REC'D 01 OCT 2004

WIPO

PCT

July 09, 2004

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.**

APPLICATION NUMBER: 60/479,871**FILING DATE: June 20, 2003**

**PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)**

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



H. L. JACKSON
Certifying Officer

JUN 20 2003 1:09PM

SWABEY OGILVY MTL 514 288 8389

NO 7273 P. 4/28
60479871
A/Pro16698 U.S. PTO
06/20/03PTO/SB/16 (10-01)
Approved for use through 10/31/2002. OMB 0551-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

16424 U.S. PTO
60/479871
06/20/03

| INVENTOR(S) | | | | |
|--|---------------------------|---|------------------------|---------|
| Given Name (first and middle (if any)) | Family Name or Surname | Residence (City and either State or Foreign Country) | | |
| Normand | BRISSON | Montréal, CANADA | | |
| Darrell Rajaropal | DESVEAUX SUBRAMANIAM | Carrboro, NC, USA Chapel Hill, NC, USA | | |
| <input checked="" type="checkbox"/> Additional inventors are being named on the 1 separately numbered sheets attached hereto | | | | |
| TITLE OF THE INVENTION (500 characters max) | | | | |
| PLANT TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF | | | | |
| Direct all correspondence to: | | CORRESPONDENCE ADDRESS | | |
| <input checked="" type="checkbox"/> Customer Number | 020988 |  020988 | | |
| OR | Type Customer Number here | | | |
| <input type="checkbox"/> Firm or Individual Name | | | | |
| Address | | | | |
| Address | | | | |
| City | State | ZIP | | |
| Country | Telephone | Fax | | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | |
| <input checked="" type="checkbox"/> Specification Number of Pages | 19 | <input type="checkbox"/> CD(s), Number | | |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets | 6 | <input type="checkbox"/> Other (specify) | | |
| <input type="checkbox"/> Application Data Sheet, See 37 CFR 1.76 | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27 | | | FILING FEE AMOUNT (\$) | |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fee | | | \$80.00 | |
| <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: | 19-5113 | | | \$80.00 |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached | | | | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | |
| <input checked="" type="checkbox"/> No. | | | | |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: | | | | |

Respectfully submitted,

SIGNATURE



Date

June 20, 2003

TYPED or PRINTED NAME

Christian Cawthorn

REGISTRATION NO.
If appropriate)

47,352

TELEPHONE

(514) 847-4256

Docket Number:

10662-121USPR

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14.

[SOR.PAT.FORM 110 - 10/2001]

JUN. 20. 2003 1:10PM

SWABEY OGILVY MTL 514 288 8389

NO. 2272 P. 5/20
60479371 000003**PROVISIONAL APPLICATION COVER SHEET**
Additional Page

Approved for use through 10/31/2002. OMB 0851-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---------------------------------------|------------------------|---|
| Docket Number | | 10662-121 USPR |
| INVENTOR(S)/APPLICANT(S) | | |
| Given Name (first and middle, if any) | Family Name or Surname | Residence (City and either State or Foreign Country) |
| Jurgen | SYGUSCH | Montreal, CANADA |

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

[SOR.PAT.FORM 110 - 102/2001]

PLANT TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF

BACKGROUND OF THE INVENTION

(a) Field of the invention

- [0001] The present invention relates to plant transcriptional activators and mutants thereof. Furthermore, the present invention relates to uses of plant transcriptional activators and mutants thereof for increasing plant defence responses to pathogens.

(b) Description of Prior Art

- [0002] A variety of defence specific events are induced in plants in response to pathogen infection. Although key components of the signaling cascades are being discovered, few transcription factors that integrate these signals at the transcriptional level have been identified to date.
- [0003] *PR* genes are plant genes that are induced by pathogen invasion. These genes are subdivided into 11 classes. Since *PR* genes are well characterized, they provide excellent models to study transcriptional regulation of defence genes.
- [0004] The *PR-10* gene family is one of the classes of *PR* genes. Expression studies have identified *cis*-acting elements involved in *PR-10a* gene regulation, a member of the *PR-10* gene family (Matton et al. 1993, Plant Mol. Biol. 22:279-291). An elicitor response element (ERE) located between nucleotides -135 and -105 is essential and sufficient for elicitor-induced expression of *PR-10a* (Després et al. 1995, Plant Cell 7:589-598). PBF-2, a single-stranded DNA binding factor, appears to play a role in activation of *PR-10a* from the ERE (Desveaux et al. 2000, Plant Cell 12:1477-1489). It has been shown that the presence of the ERE is sufficient for *PR-10a* activation. It has also been shown that the sequence that is bound by PBF-2 is GTCAAAAA. It has been shown that, *in planta*, PBF-2 binds to *PR-10a* only when this gene is activated by wounding or by treatment with an elicitor that mimics the action of a pathogen. PBF-2 is a

tetramer made of four identical 24 kD (p24) subunits (Desveaux et al. 2002, Nature Struct. Biol. 9:512-517). The sequence and secondary structure of p24 is conserved among plant species and this novel plant transcription factor has been renamed Whirly, based on the whirligig appearance of the quaternary structure of the protein. Accordingly the potato p24 has been renamed StWhy1, and its ortholog in Arabidopsis AtWhy1.

- [0005] It would be highly desirable to be provided with plant transcriptional activators, mutants thereof and uses thereof for increasing plant defence responses to pathogens.

SUMMARY OF THE INVENTION

- [0006] One aim of the present invention is to provide plant transcriptional activators and mutants thereof.
- [0007] Another aim of the present invention is to provide plant transcriptional activators and mutants thereof for increasing plant defence responses to pathogens.
- [0008] In accordance with the present invention there is provided plant transcriptional activators and mutants thereof.
- [0009] In accordance with the present invention there is also provided plant transcriptional activators and mutants thereof for increasing plant defence responses to pathogens.
- [0010] In accordance with one embodiment of the present invention there is provided a peptide which confers increased pathogen resistance upon a plant expressing the peptide, the peptide having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4 mutated at a position selected from the group consisting of Gly148, Pro183, Glu271, Trp272 and residues between and including Pro123 to Gly128, an ortholog thereof, a homolog thereof, a functionally active fragment thereof or a functionally active variant thereof.

- [0011] In accordance with another embodiment of the present invention there is provided a recombinant nucleic acid molecule comprising a sequence which codes for a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 mutated at a position selected from the group consisting of Gly148, Pro183, Glu271, Trp272 and residues between and including Pro123 to Gly128, an ortholog thereof, a homolog thereof, a functionally active fragment thereof or a functionally active variant thereof.
- [0012] A preferred recombinant nucleic acid molecule is DNA.
- [0013] Preferably a vector contains the recombinant nucleic acid molecule, more preferably an expression vector.
- [0014] A preferred recombinant nucleic acid molecule is operatively linked to an expression control sequence.
- [0015] In accordance with another embodiment of the present invention there is provided a method of expressing a recombinant nucleic acid molecule in a cell containing an expression vector of the present invention, comprising culturing the cell in an appropriate cell culture medium under conditions that provide for expression of the recombinant DNA molecule by the cell.
- [0016] A preferred method of the present invention, further comprises the step of purifying a recombinant product of the expression of the recombinant DNA molecule.
- [0017] In accordance with another embodiment of the present invention there is provided a cell transformed with the recombinant DNA molecule of the present invention.
- [0018] In a preferred embodiment of the present invention, the recombinant DNA molecule is integrated in the genome of the cell.
- [0019] A preferred cell of the present invention is a plant cell.

- [0020] In accordance with another embodiment of the present invention there is provided a plant comprising a cell of the present invention.
- [0021] In accordance with another embodiment of the present invention there is provided a transgenic plant comprising a recombinant nucleic acid molecule of the present invention.
- [0022] In a preferred transgenic plant of the present invention the recombinant nucleic acid is integrated into the genome of the cell.
- [0023] In accordance with another embodiment of the present invention there is provided a method of increasing pathogen resistance in a plant comprising the steps of: (a) introducing into a cell of the plant a recombinant nucleic acid molecule of the present invention; and (b) expressing the recombinant nucleic acid molecule in the cell.
- [0024] In accordance with another embodiment of the present invention there is provided a method of increasing pathogen resistance in a plant comprising the steps of: (a) mutating a nucleic acid sequence which codes for p24; and (b) expressing the nucleic acid sequence in the plant, wherein the mutating results in a amino acid substitution in the p24 which increases DNA binding affinity of PBF-2 for an elicitor response element (ERE).
- [0025] In a preferred method of the present invention the amino acid substitution replaces Pro125 with nothing or a different amino acid, preferably with Leu.
- [0026] In a preferred method of the present invention the amino acid substitution replaces Trp272 with nothing or a different amino acid, preferably with Ala.
- [0027] In a preferred method of the present invention the amino acid substitution replaces Glu271 with nothing or a different amino acid, preferably with any non-acidic amino acid.

- [0028]** In a preferred method of the present invention the amino acid substitution replaces Pro183 with nothing or a different amino acid, preferably with Ser.
- [0029]** In a preferred method of the present invention the amino acid substitution replaces Gly148 with nothing or a different amino acid, preferably with Glu.
- [0030]** In a preferred method of the present invention the ERE regulates expression of a pathogenesis-related (PR) gene.
- [0031]** In a preferred method of the present invention the PR gene is a PR-10 gene, preferably PR-10a.
- [0032]** In a preferred method of the present invention the step of mutating a nucleic acid sequence is effected by a chemical mutagen, radiation, natural mutation or a recombinant DNA technique, preferably site-directed mutagenesis.
- [0033]** In accordance with another embodiment of the present invention there is provided a method of increasing pathogen resistance in a plant comprising increasing DNA binding affinity of PBF-2 for an elicitor response element (ERE) of a pathogenesis-related (PR) gene.
- [0034]** In a preferred method of the present invention increasing DNA binding affinity of PBF-2 for an ERE comprises mutating a C-terminal negative autoregulatory domain of p24, wherein the C-terminal autoregulatory domain inhibits PBF-2 DNA binding and wherein the mutating decreases negative autoregulation of the domain.
- [0035]** In a preferred method of the present invention the mutating comprises an amino acid substitution in p24.
- [0036]** In a preferred method of the present invention mutating a C-terminal negative autoregulatory domain is effected by a chemical mutagen, radiation, natural mutation or a recombinant DNA technique, preferably site-directed mutagenesis.

- [0037] In a preferred method of the present invention the amino acid substitution replaces a residue between and including Pro123 to Gly128 with nothing or a different amino acid.
- [0038] For the purpose of the present invention the following terms are defined below.
- [0039] The term "ortholog" is intended to mean a gene obtained from one species that is structurally similar and is the functional counterpart of a gene from a different species. Sequence differences among orthologs are the result of speciation.
- [0040] The term "homolog" is intended to mean a gene or protein from one species, that has a common origin and functions the same as a gene or protein, respectively, from another species.
- [0041] The term "transformed" when qualifying a cell is intended to mean a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) AtWhy1, a homolog of AtWhy1, a functional mutant of AtWhy1, a functional fragment of AtWhy1, a functional fragment of a homolog of AtWhy1, and a functional fragment of a functional mutant of AtWhy1.
- [0042] The term "transgenic" is intended to mean an organism harbouring in its genome of its germ and/or somatic cells a transgene that has been introduced using recombinant technology.
- [0043] The term "transgene" is intended to mean a gene inserted into the genome of the germ and/or somatic cells of an organism in a manner that ensures its function, replication and transmission as a normal gene. A "transgene" can be any piece of a nucleic acid molecule (for example, DNA) which is inserted by artifice into a cell, and becomes part of the organism (integrated into the genome or maintained extrachromosomally) which develops from that cell. Such a transgene may include a gene which

is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous or analogous to an endogenous gene of the organism.

- [0044] The term "pathogen" is intended to mean any organism which can infect another organism.. Such infection may result in and/or induce disease in the infected organism and/or result in the death of the infected organism. Examples of pathogens include, but are not limited to, bacteria, viruses, fungi, oomycetes, insects, nematodes and plants.

BRIEF DESCRIPTION OF THE DRAWINGS

- [0045] Fig. 1 illustrates the sequence alignment of the potato StWhy1 protein sequence (SEQ ID NO:1) and the three *Arabidopsis* Whirly proteins AtWhy1 (gi5223748) (SEQ ID NO:2), AtWhy2 (gi18175814) (SEQ ID NO:3) and AtWhy3 (gi15227028) (SEQ ID NO:4);
- [0046] Fig. 2 illustrates that mutations in *Arabidopsis* AtWhy1 lead to change in the susceptibility of *Arabidopsis thaliana* cotyledons to infection by *Peronospora parasitica* Noco2, as quantified by counting sporangia on cotyledons 7 days after infection;
- [0047] Fig. 3 illustrates wild type Col-0 *Arabidopsis* plants and AtWhy1 TILLING lines till1, till2 and till3 infected with the compatible oomycete pathogen *P. parasitica* isolate Noco2;
- [0048] Fig. 4 illustrates that the extreme C-terminal domain of StWhy1 interacts with and appears to interfere with the DNA-binding surface of StWhy1 through an interaction mediated mainly through Lys188 and Trp272, as well as Glu271 and His174; and
- [0049] Fig. 5 illustrates that mutation of Trp272 increases the DNA-binding affinity of StWhy1 and shows (A) the mutation mW272 causes a change in electrophoretic mobility relative to wild type StWhy1, (B) a bar graph quantitatively representing the amount of probe shifted by each protein in (A) relative to wild type StWhy1 (StWhy1 = 1.0), and (C) immunoblot analysis of extracts used for EMSA analysis in (A) using antibody raised

against recombinant StWhy1 to show equal loading of the Wt and m272 proteins.

DETAILED DESCRIPTION OF THE INVENTION

[0050] Sequence alignment of the potato StWhy1 protein sequence (SEQ ID NO:1) and the three *Arabidopsis* Whirly proteins AtWhy1 (gi5223748) (SEQ ID NO:2), AtWhy2 (gi18175814) (SEQ ID NO:3) and AtWhy3 (gi15227028) (SEQ ID NO:4) is shown in Fig. 1. The alignment was initially performed using ClustalW (Thompson et al. 1994, Nucl. Acids Res. 22:4673-4680) and was subsequently manually modified. Numbering corresponds to the StWhy1 protein. Conserved residues (100% between all four members) are boxed in black and positions with conserved similar residues are boxed in grey. The consensus protein sequence obtained from the alignment is indicated at the bottom.

[0051] The secondary structure predicted by the program PDH indicates that these sequences are likely to adopt a secondary structure similar to that of potato p24 (Desveaux et al. 2002, *supra*).

[0052] Arabidopsis lines containing single point mutations in the sequence of AtWhy1 were obtained from the Arabidopsis Tilling Project (McCallum et al. 2000, Nature Biotechnol. 18:455-457). Three Arabidopsis lines, till1, till2 and till3 possessing point mutations in AtWhy1 were obtained by TILLING. The mutation in line till1 changes Pro125 to Leu, till2 changes Pro183 to a Ser and the mutation in till3 changes Gly148 to a Glu. The mutations in the Arabidopsis TILLING lines are marked by an asterisk in Fig. 1, as well as the amino acids Trp272 and Glu271 believed to negatively regulate DNA-binding activity. These lines were produced by treatment of Arabidopsis seeds with a mutagenizing agent.

[0053] Fig. 2 shows the susceptibility to infection by *Peronospora parasitica* isolate Noco2 of wild type *Arabidopsis thaliana* Col-0, of two mutant lines that show increased susceptibility to this pathogen (lines till2 and till3), and of the (Pro125 to Leu) mutant line (till1), which shows decreased

susceptibility to infection. Mutations in *Arabidopsis AtWhy1* that lead to change in the susceptibility to infection by *Peronospora parasitica* isolate Noco2 were quantified by counting sporangia on cotyledons 7 days after infection. Cotyledons were scored as either having 0-5, 6-15 or greater than 15 sporangia. Bars of the histogram represent the percentage of cotyledons falling into the three categories of sporangia counts for each genotype infected. Each category is represented by a different bar color: green (bar 1), 0-5 sporangia; yellow (bar 2), 6-15 sporangia; (bar 3) red, more than 15 sporangia per cotyledon.

[0054] These results are confirmed by staining infected cotyledons with Trypan Blue. Wild type Col-0 *Arabidopsis* plants and *AtWhy1* TILLING lines till1, till2 and till3 were infected with the compatible oomycete pathogen *P. parasitica* isolate Noco2. Hyphal growth was then examined by Trypan Blue staining leaves 2 days after infection (Fig. 3).

[0055] Replacement of Pro125 with amino acids other than leucine and the modification of amino acid residues surrounding Pro125 also lead to increased resistance to pathogens.

[0056] The above results suggest that the mutation Pro125 to Leu in *AtWhy1* is dominant. It is therefore predicted that overexpression of this mutant *AtWhy1* gene in *Arabidopsis thaliana* would also confer a disease resistant phenotype. Transformation of any plants with the *AtWhy1* mutant gene bearing the Pro125 to Leu mutation, or an homolog of *AtWhy1* with a similar mutation, should confer to this plant an increased resistance to pathogens.

[0057] Sequence comparison of Whirly family members reveals that Lys188 is conserved among these proteins (Desveaux et al, 2002, *supra*; Fig. 1). Furthermore, the side chain of this residue is exposed to the solvent and its position suggests that it could make contact with single-stranded DNA (ssDNA) (Fig.4). Interestingly, the crystal structure of PBF-2 revealed that this residue interacts with Trp272 located at the C-terminus (Fig. 4). This interaction positions the C-terminus across the β -sheet

surface of PBF-2, where it could interfere with DNA binding. As shown in Fig. 4 the extreme C-terminal domain of StWhy1 interacts with and appears to interfere with the DNA-binding surface of StWhy1 through an interaction mediated mainly through Lys188 and Trp272, as well as Glu271 and His174. The DNA binding surface of a PBF-2 protomer is depicted as a ribbon diagram in Fig. 4 with the side chains of conserved amino acid residues predicted to be important for ssDNA binding affinity indicated. Amino acids of the KGKAAL sequence known to be critical for DNA binding activity are located at positions 100-105, those of the YDW sequence in loop L₃₄ are at positions 143-145, the extreme C-terminal backbone containing Trp272 is labelled as C-terminus, and the position of Lys188 is indicated by an arrow.

[0058] Mutation of Lys188 abolished PBF-2 DNA binding activity in Electro Mobility Shift Assays, confirming the importance of this residue for DNA binding. Therefore, the C-terminus may not only act as a barrier to the ssDNA, but could compete with the DNA for interaction with Lys188.

[0059] As shown in Fig. 5, mutation of Trp272 to Ala in the C-terminus of StWhy1 (Fig. 1; mW272) resulted in a 3.5-fold increase in DNA binding affinity, indicating that the C-terminal region of p24 could act as a negative autoregulatory domain. Trp272, which appears to be important for interacting with the DNA-binding surface of StWhy1 was mutated and its effect on DNA binding activity was examined. Fig. 5A shows the EMSA analysis of wild type StWhy1 and the mutations mW272 and mK188 with the non-coding strand of the ERE as probe using 80 nM of protein in each reaction. Note that the mutation mW272 causes a change in electrophoretic mobility relative to wild type StWhy1, suggesting a possible important conformational change. Fig. 5B: shows a bar graph quantitatively representing the amount of probe shifted by each protein in Fig. 5A relative to wild type StWhy1 (StWhy1 = 1.0). Quantitation of DNA bound by StWhy1 was assessed by liquid scintillation counting of the retarded band excised from the gel. Fig. 5C shows an immunoblot analysis

of extracts used for EMSA analysis in Fig. 5A using antibody raised against recombinant StWhy1 to show equal loading of the Wt and mW272 proteins. It is expected that the majority of amino acids, particularly those similar to Ala, would give similar results.

[0060] Therefore, mutation of Trp272 which leads to increase binding of PBF-2 to DNA would lead to increased resistance to pathogens. This is supported by the observation that the AtWhy1 mutant protein in the till3 line (highly susceptible to infection, Figs. 2 and 3) binds significantly less to DNA than wild type AtWhy1. This indicates that a correlation exists between the extent of binding to DNA and disease resistance. The Trp272 mutation could be obtained through mutagenesis of the wild type gene *in planta*. Alternatively plants could be rendered more resistant by transformation with the Trp272 mutant allele, using such techniques as, but not limited to, Agrobacterium mediated transformation, particle bombardment, direct DNA transformation, viral vector infection, electroporation, and micro-injection.

[0061] Examination of the crystal structure of PBF2 revealed that a second amino acid, Glu271, also contributes to the interaction of the C-terminus across the β -sheet surface of PBF-2. It is therefore anticipated that mutation of this residue will also lead to increased DNA binding, and therefore to an increased resistance to pathogens.

[0062] The present invention also shows that another point mutation (Pro125 to Leu) in the sequence of AtWhy1 (till1) also confers to the plant *Arabidopsis thaliana* an increased resistance to infection by the pathogen *Peronospora parasitica* isolate Noco2 (Figs. 2 and 3). These figures show that less sporangia and hyphal growth are present in till1 plants infected with the oomycete as compared to wild type plants infected with the same pathogen. By contrast, point mutations in the till2 and till3 lines lead to increase susceptibility to infection by *P. parasitica*, confirming the importance of AtWhy1 in disease resistance.

[0063] These results indicate that it would be possible to screen for the presence of these mutations in Whirly genes in any plant species and that these mutations would confer increased resistance to infection by pathogens. These mutations could be induced by any means, including but not limited to, chemical, radiation, natural, or alternatively by using recombinant DNA techniques such as site-directed mutagenesis on an isolated nucleic acid sequence.

[0064] Similar mutations in other Whirly gene family members are also expected to lead to resistance to infection.

[0065] The present invention is not intended to be limited only to peptide sequences for the transcriptional activators disclosed (either wild-type or mutant), but is intended to also include nucleic acid sequences which code for such transcriptional activator peptide sequences. The nucleic acid sequences can be recombinant nucleic acid molecules and may include DNA and RNA. Cloning and propagation of these nucleic acid molecules can be achieved by techniques commonly known and used in the art, such as by incorporating the nucleic acid molecules into vectors which can be transformed and/or transfected into bacterial or other host systems for maintenance and propagation thereof.

[0066] Expression of such peptides in a transformed host cell (for example, such as in a bacterial, fungal or plant cell) can be achieved by techniques commonly known and used in the art. For example, a recombinant nucleic acid molecule can be operatively linked to an expression control sequence in an expression vector. The expression vector can then be used to transform a host cell using techniques commonly known and used in the art, such as for example, *Agrobacterium* mediated transformation. The transformed host may be, for example, a single cell, or a callus of cells or plant produced by culturing the cell *in vitro*. Expression of the peptide in the transformed host can then be achieved by the appropriate measures, for example, by culturing the cell in an appropriate cell culture medium *in vitro* under conditions that provide for expression of the recombinant

nucleic acid molecule by the cell, or by the application of an appropriate inducer.

[0067] Such transformed hosts can be used to produce large quantities of such peptides which can be isolated and purified from such transformed hosts. A vector transformed into a host cell may remain separate from the genome of the host or it may become integrated within the genome of the host. Transformed hosts are considered to be transgenic.

[0068] A transgenic plant possessing a nucleic acid as discussed above and expressing the peptide coded by the nucleic acid would display increased pathogen resistance over a non-transgenic plant.

[0069] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A peptide which confers increased pathogen resistance upon a plant expressing said peptide, said peptide having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4 mutated at a position selected from the group consisting of Glu271, Trp272 and residues between and including Pro123 to Gly128, an ortholog thereof, a homolog thereof, a functionally active fragment thereof or a functionally active variant thereof.
2. A recombinant nucleic acid molecule comprising a sequence which codes for a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 mutated at a position selected from the group consisting of Glu271, Trp272 and residues between and including Pro123 to Gly128, an ortholog thereof, a homolog thereof, a functionally active fragment thereof or a functionally active variant thereof.
3. The recombinant nucleic acid molecule of claim 2, wherein said nucleic acid is DNA.
4. A vector containing the recombinant nucleic acid molecule of claim 2.
5. The recombinant nucleic acid molecule of claim 3, wherein said DNA sequence is operatively linked to an expression control sequence.
6. An expression vector containing the recombinant DNA molecule of claim 5.
7. A method of expressing a recombinant nucleic acid molecule in a cell containing the expression vector of claim 6, comprising culturing

- the cell in an appropriate cell culture medium under conditions that provide for expression of the recombinant DNA molecule by the cell.
8. The method of claim 7, further comprising the step of purifying a recombinant product of the expression of the recombinant DNA molecule.
 9. A cell transformed with the recombinant DNA molecule of claim 2.
 10. The cell of claim 9, wherein said recombinant DNA molecule is integrated in the genome of said cell.
 11. The cell of claim 9, wherein said cell is a plant cell.
 12. A plant comprising the cell of claim 11.
 13. A transgenic plant comprising the recombinant nucleic acid molecule of claim 2.
 14. The transgenic plant of claim 13, wherein said recombinant nucleic acid is integrated into the genome of said cell.
 15. A method of increasing pathogen resistance in a plant comprising the steps of: (a) introducing into a cell of said plant a recombinant nucleic acid molecule as defined in claim 2; and (b) expressing said recombinant nucleic acid molecule in said cell.
 16. A method of increasing pathogen resistance in a plant comprising the steps of: (a) mutating a nucleic acid sequence which codes for p24; and (b) expressing said nucleic acid sequence in said plant, wherein said mutating results in a amino acid substitution in said p24 which increases DNA binding affinity of PBF-2, for an elicitor response element (ERE).

17. The method of claim 16, wherein said amino acid substitution replaces Pro125 with nothing or a different amino acid.
18. The method of claim 16, wherein said amino acid substitution is Pro125 to Leu.
19. The method of claim 16, wherein said amino acid substitution replaces Trp272 with nothing or a different amino acid.
20. The method of claim 16, wherein said amino acid substitution is Trp272 to Ala.
21. The method of claim 16, wherein said amino acid substitution replaces Glu271 with nothing or a different amino acid.
22. The method of claim 16, wherein said amino acid substitution is Glu271 to any non-acidic amino acid.
23. The method of claim 16, wherein said ERE regulates expression of a pathogenesis-related (PR) gene.
24. The method of claim 23, wherein said PR gene is a PR-10 gene.
25. The method of claim 24, wherein said PR gene is PR-10a.
26. The method of claim 16, wherein the step of mutating a nucleic acid sequence is effected by a chemical mutagen, radiation, natural mutation or a recombinant DNA technique.
27. The method of claim 26, wherein said recombinant DNA technique is site-directed mutagenesis.
28. A method of increasing pathogen resistance in a plant comprising increasing DNA binding affinity of PBF-2 for an elicitor response element (ERE) of a pathogenesis-related (PR) gene.

29. The method of claim 28, wherein increasing DNA binding affinity of PBF-2 for an ERE comprises mutating a C-terminal negative autoregulatory domain of p24, wherein said C-terminal autoregulatory domain inhibits PBF-2 DNA binding and wherein said mutating decreases negative autoregulation of said domain.
30. The method of claim 29, wherein said mutating comprises an amino acid substitution in p24.
31. The method of claim 30, wherein said amino acid substitution replaces Pro125 with nothing or a different amino acid.
32. The method of claim 30, wherein said amino acid substitution is Pro125 to Leu.
33. The method of claim 30, wherein said amino acid substitution replaces Trp272 with nothing or a different amino acid.
34. The method of claim 30, wherein said amino acid substitution replaces Trp272 with Ala.
35. The method of claim 30, wherein said amino acid substitution replaces Glu271 with nothing or a different amino acid.
36. The method of claim 30, wherein said amino acid substitution replaces Glu271 with any non-acidic amino acid.
37. The method of claim 28, wherein said mutating a C-terminal negative autoregulatory domain is effected by a chemical mutagen, radiation, natural mutation or a recombinant DNA technique.
38. The method of claim 37, wherein said recombinant DNA technique is site-directed mutagenesis.

39. The method of claim 16, wherein said amino acid substitution replaces a residue between and including Pro123 to Gly128 with nothing or a different amino acid.
40. The method of claim 30, wherein said amino acid substitution replaces a residue between and including Pro123 to Gly128 with nothing or a different amino acid.

ABSTRACT OF THE INVENTION

The present invention relates to plant transcriptional activators and mutants thereof. Furthermore, the present invention relates to uses of plant transcriptional activators and mutants thereof for increasing plant defence responses to pathogens. In particular, the present invention relates to a peptide which confers increased pathogen resistance upon a plant expressing said peptide, said peptide having a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4 mutated at a position selected from the group consisting of Glu271, Trp272 and residues between and including Pro123 to Gly128, an ortholog thereof, a homolog thereof, a functionally active fragment thereof or a functionally active variant thereof.

Figure 1

| | | | | | | | |
|-----------|-----|-----|-----|-----|-----|-----|-----|
| Seq1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq2 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq3 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Consensus | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq2 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq3 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Consensus | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| Seq1 | 80 | 90 | 100 | 110 | 120 | 130 | 140 |
| Seq2 | 80 | 90 | 100 | 110 | 120 | 130 | 140 |
| Seq3 | 80 | 90 | 100 | 110 | 120 | 130 | 140 |
| Consensus | 80 | 90 | 100 | 110 | 120 | 130 | 140 |
| Seq1 | 150 | 160 | 170 | 180 | 190 | 200 | 210 |
| Seq2 | 150 | 160 | 170 | 180 | 190 | 200 | 210 |
| Seq3 | 150 | 160 | 170 | 180 | 190 | 200 | 210 |
| Consensus | 150 | 160 | 170 | 180 | 190 | 200 | 210 |
| Seq1 | 220 | 230 | 240 | 250 | 260 | 270 | 280 |
| Seq2 | 220 | 230 | 240 | 250 | 260 | 270 | 280 |
| Seq3 | 220 | 230 | 240 | 250 | 260 | 270 | 280 |
| Consensus | 220 | 230 | 240 | 250 | 260 | 270 | 280 |




Figure 2


Figure 3



Wt Col-0



tll1



tll2



tll3

Figure 4





Figure 5



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.